Ironwood Pharmaceuticals, Inc. (IRWD)

$7.79

-0.09

(-1.14%)▲

Market is closed - opens 7 PM, 16 Apr 2024

Insights on Ironwood Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 104.06M → 117.55M (in $), with an average increase of 4.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 15.32M → -1.08M (in $), with an average decrease of 107.1% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 31.0% return, outperforming this stock by 59.3%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 39.4% return, outperforming this stock by 65.1%

Performance

  • $7.71
    $7.92
    $7.79
    downward going graph

    1.03%

    Downside

    Day's Volatility :2.65%

    Upside

    1.64%

    downward going graph
  • $7.79
    $15.70
    $7.79
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :50.38%

    Upside

    50.38%

    downward going graph

Returns

PeriodIronwood Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-32.88%
-0.6%
0.0%
6 Months
-19.59%
5.9%
0.0%
1 Year
-29.83%
3.2%
-0.7%
3 Years
-25.73%
14.3%
-21.8%

Highlights

Market Capitalization
1.2B
Book Value
- $2.21
Earnings Per Share (EPS)
-6.45
PEG Ratio
-0.26
Wall Street Target Price
18.0
Profit Margin
-226.37%
Operating Margin TTM
3.16%
Return On Assets TTM
13.39%
Return On Equity TTM
-674.04%
Revenue TTM
442.7M
Revenue Per Share TTM
2.85
Quarterly Revenue Growth YOY
9.700000000000001%
Gross Profit TTM
366.3M
EBITDA
169.9M
Diluted Eps TTM
-6.45
Quarterly Earnings Growth YOY
-0.68
EPS Estimate Current Year
0.68
EPS Estimate Next Year
0.81
EPS Estimate Current Quarter
0.21
EPS Estimate Next Quarter
0.15

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Ironwood Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 131.07%

Current $7.79
Target $18.00

Company Financials

FY18Y/Y Change
Revenue
346.6M
↑ 16.21%
Net Income
-282.4M
↑ 141.47%
Net Profit Margin
-81.46%
↓ 42.26%
FY19Y/Y Change
Revenue
428.4M
↑ 23.59%
Net Income
-15.3M
↓ 94.58%
Net Profit Margin
-3.57%
↑ 77.89%
FY20Y/Y Change
Revenue
389.5M
↓ 9.08%
Net Income
106.2M
↓ 793.33%
Net Profit Margin
27.26%
↑ 30.83%
FY21Y/Y Change
Revenue
413.8M
↑ 6.22%
Net Income
528.4M
↑ 397.71%
Net Profit Margin
127.72%
↑ 100.46%
FY22Y/Y Change
Revenue
410.6M
↓ 0.76%
Net Income
175.1M
↓ 66.87%
Net Profit Margin
42.64%
↓ 85.08%
FY23Y/Y Change
Revenue
442.7M
↑ 7.83%
Net Income
-1.0B
↓ 672.5%
Net Profit Margin
-226.37%
↓ 269.01%
Q3 FY22Q/Q Change
Revenue
108.6M
↑ 11.73%
Net Income
50.3M
↑ 35.7%
Net Profit Margin
46.32%
↑ 8.18%
Q4 FY22Q/Q Change
Revenue
107.2M
↓ 1.32%
Net Income
48.9M
↓ 2.88%
Net Profit Margin
45.59%
↓ 0.73%
Q1 FY23Q/Q Change
Revenue
104.1M
↓ 2.93%
Net Income
45.7M
↓ 6.45%
Net Profit Margin
43.93%
↓ 1.66%
Q2 FY23Q/Q Change
Revenue
107.4M
↑ 3.19%
Net Income
-1.1B
↓ 2423.55%
Net Profit Margin
-989.17%
↓ 1033.1%
Q3 FY23Q/Q Change
Revenue
113.7M
↑ 5.92%
Net Income
15.3M
↓ 101.44%
Net Profit Margin
13.47%
↑ 1002.64%
Q4 FY23Q/Q Change
Revenue
117.6M
↑ 3.35%
Net Income
-1.1M
↓ 107.09%
Net Profit Margin
-0.92%
↓ 14.39%
FY18Y/Y Change
Total Assets
332.1M
↓ 45.18%
Total Liabilities
528.4M
↓ 11.31%
FY19Y/Y Change
Total Assets
402.7M
↑ 21.29%
Total Liabilities
496.0M
↓ 6.14%
FY20Y/Y Change
Total Assets
559.2M
↑ 38.86%
Total Liabilities
496.6M
↑ 0.12%
FY21Y/Y Change
Total Assets
1.1B
↑ 101.51%
Total Liabilities
521.0M
↑ 4.92%
FY22Y/Y Change
Total Assets
1.1B
↓ 2.34%
Total Liabilities
448.1M
↓ 13.99%
FY23Y/Y Change
Total Assets
471.1M
↓ 57.2%
Total Liabilities
817.4M
↑ 82.39%
Q3 FY22Q/Q Change
Total Assets
1.0B
↑ 6.63%
Total Liabilities
449.3M
↑ 1.46%
Q4 FY22Q/Q Change
Total Assets
1.1B
↑ 5.78%
Total Liabilities
448.1M
↓ 0.25%
Q1 FY23Q/Q Change
Total Assets
1.2B
↑ 4.98%
Total Liabilities
448.4M
↑ 0.06%
Q2 FY23Q/Q Change
Total Assets
603.2M
↓ 47.79%
Total Liabilities
950.0M
↑ 111.85%
Q3 FY23Q/Q Change
Total Assets
524.1M
↓ 13.12%
Total Liabilities
849.7M
↓ 10.55%
Q4 FY23Q/Q Change
Total Assets
471.1M
↓ 10.11%
Total Liabilities
817.4M
↓ 3.81%
FY18Y/Y Change
Operating Cash Flow
-70.9M
↓ 28.81%
Investing Cash Flow
88.9M
↓ 41.33%
Financing Cash Flow
30.1M
↑ 51.61%
FY19Y/Y Change
Operating Cash Flow
10.7M
↓ 115.13%
Investing Cash Flow
-11.1M
↓ 112.54%
Financing Cash Flow
-1.2M
↓ 103.94%
FY20Y/Y Change
Operating Cash Flow
168.8M
↑ 1474.23%
Investing Cash Flow
-1.8M
↓ 83.47%
Financing Cash Flow
18.5M
↓ 1665.06%
FY21Y/Y Change
Operating Cash Flow
261.9M
↑ 55.12%
Investing Cash Flow
-265.0K
↓ 85.61%
Financing Cash Flow
-4.6M
↓ 124.53%
FY22Y/Y Change
Operating Cash Flow
273.8M
↑ 4.53%
Investing Cash Flow
-136.0K
↓ 48.68%
Financing Cash Flow
-237.6M
↑ 5120.95%
Q3 FY22Q/Q Change
Operating Cash Flow
69.1M
↑ 12.59%
Investing Cash Flow
-66.0K
↓ 25.0%
Financing Cash Flow
797.0K
↓ 100.53%
Q4 FY22Q/Q Change
Operating Cash Flow
79.2M
↑ 14.6%
Investing Cash Flow
27.0K
↓ 140.91%
Financing Cash Flow
2.8M
↑ 252.07%
Q1 FY23Q/Q Change
Operating Cash Flow
80.2M
↑ 1.25%
Investing Cash Flow
-13.0K
↓ 148.15%
Financing Cash Flow
4.0M
↑ 41.87%
Q2 FY23Q/Q Change
Operating Cash Flow
35.0M
↓ 56.39%
Investing Cash Flow
-999.5M
↑ 7688300.0%
Financing Cash Flow
399.1M
↑ 9924.39%

Technicals Summary

Sell

Neutral

Buy

Ironwood Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
-12.64%
-19.59%
-29.83%
-25.73%
-30.88%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.19%
18.54%
29.33%
41.75%
58.78%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-3.61%
-2.91%
-7.72%
8.1%
8.1%
Zoetis Inc.
Zoetis Inc.
-12.13%
-14.39%
-14.11%
-9.35%
51.24%
Viatris Inc.
Viatris Inc.
-5.11%
19.64%
14.33%
-14.68%
-30.66%
Catalent, Inc.
Catalent, Inc.
0.14%
21.02%
23.93%
-49.1%
32.28%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
9.67
NA
-0.26
0.68
-6.74
0.13
NA
-2.21
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
55.91
55.91
0.45
4.77
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.61
28.61
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.58
29.58
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
226.6
226.6
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.08
0.45
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Buy
$1.2B
-30.88%
9.67
-226.37%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.7B
58.78%
55.91
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
8.1%
28.61
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.5B
51.24%
29.58
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.5B
-30.66%
226.6
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.3B
32.28%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    16.60%

  • Sarissa Capital Management LP

    10.47%

  • Vanguard Group Inc

    10.24%

  • State Street Corporation

    7.37%

  • LSV Asset Management

    4.33%

  • Renaissance Technologies Corp

    4.21%

Company Information

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Organization
Ironwood Pharmaceuticals, Inc.
Employees
267
CEO
Ms. Julie H. McHugh
Industry
Health Technology

Discover More

FAQs